

Investor Conference 2022



科妍生物科技股份有限公司
SciVision Biotech Inc.

Dr. Chun Chang Chen

Disclaimer

This slide contains our business prospect, financial condition and sales prognosis which are derived from our existing internal/external data analysis. The actual result of operations may differ from the expressed or implied in these forward-looking statements due to various reasons, including but not limited to price fluctuation, competition, global economic condition, exchange rate fluctuation, market demand or other risks that beyond our control.

The forward-looking statements in this release reflect the current belief of SciVision at this point and SciVision undertakes no obligation to update these statements with new information or future events.

Outline

1. Company & Product & Technology Overview
2. Business Operation

About SciVision Biotech Inc.





SciVISION
BIOTECH INC.

- Established in 2001
- Listed on TSE in 2013 (Code: 1786)
- **Professional high-class, pharmaceutical-grade Hyaluronic Acid medical device production**
- Two factories are located at No. 1, S. 1st Rd., and No. 9, S. 6th Rd., Qianzhen Dist., Kaohsiung City, Taiwan
- Received certificates of QMS and ISO 13485 and complied with the regulations of the US FDA PIC/s GMP, etc.




Core Technologies

(Crosslinked Hyaluronic Acid Platform, CHAP[®])



Absorbable adhesion barrier




Single-injection viscosupplement



Dermal filler



Other new application category products



Intellectual Property Protection of CHAP


US09371402B2

(12) **United States Patent**
Chen et al.

(10) **Patent No.:** US 9,371,402 B2
(45) **Date of Patent:** Jun. 21, 2016

(54) **METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID**

(75) **Inventors:** **Tse-Chern Chen, Kaohsiung (TW); Li-Seo Chen, Kaohsiung (TW)**

(73) **Assignee:** **SCIVISION BIOTECH INC., K.E.P.Z. (TW)**

(*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 351 days.

(21) **Appl. No.:** 13/316,849
(22) **Filed:** Dec. 12, 2011
(65) **Prior Publication Data**
US 2012/0095206 A1 Apr. 19, 2012

Related U.S. Application Data
(63) Continuation-in-part of application No. 12/385,502, filed on Apr. 9, 2009, now abandoned.

(51) **Int. Cl.**
C08B 37/08 (2006.01)
U.S. Cl.

(52) **Field of Classification Search**
CPC: C08B 37/0972 (2013.01)
CPC: C08B 37/09, C08B 15/00, A61K 8/73, A61K 31/715
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

發明專利

(19) 中华人民共和国国家知识产权局

(21) 申请号 200810172329.6 I-B.

(22) 申请日 2008.10.31 审查员 张娜

(73) 专利权人 科妍生物科技股份有限公司
地址 中国台湾高雄市

(72) 发明人 陈拓成 陈丽凤

(74) 专利代理机构 北京律盟知识产权代理有限公司
代理人 刘国伟 责任公司 11287

(51) Int. Cl.
C08B 3/24 (2006.01)
C08L 5/08 (2006.01)
C08B 5/153 (2006.01)

(56) 对比文件
CN 101244290 A, 2008.08.20, 权利要求 1-5.
CN 1774272 A, 2006.05.17, 全文。
CN 101153061 A, 2008.04.02, 全文。
US 2007/0026670 A1, 2007.02.01, 权利要求 36-38.
CN 101244290 A, 2008.08.20, 权利要求

(54) **發明名稱**
交聯透明質酸的製造方法

(57) **摘要**
本发明涉及一种制造交联透明质酸的方法，其包含在约 10℃至约 30℃的低温下使包含透明质酸的溶液进行交联反应超过约 48 小时，本发明的方法不需纯化步骤即可降低交联剂的含量。

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

代表人：(中文/英文)
韓開程
HAN, KAI-CHENG

住所或營業所地址：(中文/英文)
高雄市806前鎮區高雄加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：(中文/英文)
中華民國 R.O.C.

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

代表人：(中文/英文)
韓開程
HAN, KAI-CHENG

住所或營業所地址：(中文/英文)
高雄市806前鎮區高雄加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：(中文/英文)
中華民國 R.O.C.

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

代表人：(中文/英文)
韓開程
HAN, KAI-CHENG

住所或營業所地址：(中文/英文)
高雄市806前鎮區高雄加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：(中文/英文)
中華民國 R.O.C.

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

代表人：(中文/英文)
韓開程
HAN, KAI-CHENG

住所或營業所地址：(中文/英文)
高雄市806前鎮區高雄加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：(中文/英文)
中華民國 R.O.C.

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

代表人：(中文/英文)
韓開程
HAN, KAI-CHENG

住所或營業所地址：(中文/英文)
高雄市806前鎮區高雄加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：(中文/英文)
中華民國 R.O.C.

United States

China

Taiwan

China

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

代表人：(中文/英文)
韓開程
HAN, KAI-CHENG

住所或營業所地址：(中文/英文)
高雄市806前鎮區高雄加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：(中文/英文)
中華民國 R.O.C.

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

代表人：(中文/英文)
韓開程
HAN, KAI-CHENG

住所或營業所地址：(中文/英文)
高雄市806前鎮區高雄加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：(中文/英文)
中華民國 R.O.C.

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

代表人：(中文/英文)
韓開程
HAN, KAI-CHENG

住所或營業所地址：(中文/英文)
高雄市806前鎮區高雄加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：(中文/英文)
中華民國 R.O.C.

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

代表人：(中文/英文)
韓開程
HAN, KAI-CHENG

住所或營業所地址：(中文/英文)
高雄市806前鎮區高雄加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：(中文/英文)
中華民國 R.O.C.

發明專利說明書 公告本

(本說明書格式、順序及標號字，請勿任意更改，※此號部分請勿填寫)

※ 申請案號：**97136520** **C08B37/04** (2006.01)
※ 申請日期：**97.09.23** ※ IPC 分類：**C08B**
08L5/08 (2006.01)

一、發明名稱：(中文/英文)
交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人：(共 1 人)
姓名或名稱：(中文/英文)
科妍生物科技股份有限公司
SCIVISION BIOTECH INC.

代表人：(中文/英文)
韓開程
HAN, KAI-CHENG

住所或營業所地址：(中文/英文)
高雄市806前鎮區高雄加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：(中文/英文)
中華民國 R.O.C.


EU

EU

Japan

Japan


Core Products of SciVision




Facial Aesthetics



Geriatrics care



Surgery



Urinary



Market research on global market value and growth rate


Applied field	Items	Global market value in 2021	CAGR
Facial Aesthetics	Dermal Filler	2.0 billion	9.0 %
Geriatrics Care	Synovial Fluid Supplement	2.4 billion	6.1 %
Surgery	Absorbable Adhesion Barrier	3.6 billion	8.9 %
Urinary	Intravesical Instillation	1.4 billion	5.4 %

1. Facial Aesthetics (Botulinum Toxin, Dermal Fillers), GlobalData
2. Hyaluronic Acid Viscosupplementation | Medtech 360 | Market Analysis | Global | DRG
3. ANTI-ADHESION PRODUCTS 2012, Global Industry Analysts, Inc.
4. Global Interstitial Cystitis Drugs Market Size By Type (Oral Therapy, and Intravesical Therapy). Verifiedmarketresearch

Classification of HA Dermal Filler

Gel type vs Particle type

Based on the gel type, HA facial dermal implant can be divided into monophasic type and biphasic type. The leading brand for each type is Juvederm from Allergan and Restylane from Galderma respectively.



monophasic(Gel type)
Allergan Juvederm



biphasic(Particle type)
Galderma Restylane

HA Dermal Filler

Monophasic Fillers (Gel type)



Product advantages

- ✓ High safety performance
- ✓ Smooth and natural
- ✓ Easy operation

Biphasic Fillers (Particle type)



Product advantages


- ✓ High safety performance
- ✓ Strong structural support
- ✓ Shift resistance
- ✓ Excellent viscoelasticity
- ✓ Sufficient active ingredients
- ✓ Good resistance to degradation

Benchmark Comparison



The texture of gel of ANiMERS is as smooth as that of Juvéderm

Biphasic HA Fillers of SciVision are very supportive



Biphasic HA
Fillers of
SciVision



Traditional
biphasic HA
Fillers

Traditional
Monophasic
HA Fillers



Clinical Trials and Publications

1. A Guide to Cheek Augmentation: Single-Point Deep Injection of Hyaluronic Acid Filler at Midface in Close Proximity to Medial Suborbicularis Oculi Fat (SOOF) Area. *Journal of Cosmetics, Dermatological Sciences and Applications*. 2016 Jan 06(01):1-8.
2. Use of High-Resolution Ultrasound (HRU) in the Assessment of Deep Injections of CHAP-Hyaluronic Acid (CHAP-HA) Fillers for Midface Lift. *Journal of Cosmetics, Dermatological Sciences and Applications*. 2018 Jan 08(03):126-132.
3. Dual-Plane Injection Technique With Microscale Tumescent Solution for Asian Rhinoplasty. *Dermatol Surg*. 2021 Jul 1;47(7):1015-1016.
4. CHAP-hyaluronic acid (CHAP-HA) filler as an optimal candidate for forehead filler augmentation using a 3-point injection technique. *Journal of Cosmetics, Dermatological Sciences and Applications*. 2021 Jan 11(02):76-83.

Product injected around the eye was safe and effective, with high usage satisfaction



Figure 5. Before (upper) and immediately after (lower) single point deep injection of HA filler (1ml on each side) for cheek augmentation using 27 G sharp needle. Satisfactory results were noted with minimal bruising. Left: Case 2, Right: Case 7.

Product has good tissue compatibility







Figure 5. High-resolution ultrasound imaging immediately after HA injection (a, d, g, j), at 2-Week (d, e, h, k) and 4-week (c, f, i, l) follow up. Hydration of the HA would occur (arrows), and the ha would appear to be more heterogenous and hyperechoic (arrowheads) and may become completely unidentifiable with the surrounding tissues in the 4th week follow up (i, j).

Develop injection guidelines for high-risk areas




Guidelines for forehead augmentation









Future research and development direction

Collagen Stimulator



Stimulate collagen production



Absorbable polymeric materials such as **polymethyl methacrylate**, **short peptides**, **calcium hydroxyapatite**, **polylactic acid**, or **polycaprolactone** induce fibroblasts to synthesize collagen.

Implants of the polymeric materials will be developed in the future to expand the indications for stimulating collagen proliferation.

II. Synovial Fluid Supplement



1 injection for 12 months



1 injection for 6 months
Anti-free Radical Protection Type



1 injection for 6 months



3 injection for 6 months

Anti-free Radical Protection Type

JETKNEE Synovial Fluid Supplement



Product advantages

- ✓ 1 injection for 6 months
- ✓ Anti-free Radical Protection Type
- ✓ Free of animal origin
- ✓ Easy to operate




節膝關節腔注射劑

JETKNEE



Synovial Fluid Supplement
Sterile Sodium Hyaluronate Solution

Degradation Test with ROS (H_2O_2)



JETKNEE, containing 2% HA with addition of Mannitol prolongs the protective effect of HA in the joints by removing free radicals.


Synovial Fluid Supplement

Product category	Treatment description	Global CAGR of treatments	Products
1-injection regimen (Long-acting)	Effect could be lasted for more than half a year with administrating 1 syringe.	10.2%	 <p>1 injection for 6 months 1 syringe per year Super Long-Acting Type Anti-free Radical Protection Type</p>
3-injection regimen	Effect could be lasted for half a year with administrating 3 syringes continuously, 1 syringe per week.	5.9%	 <p>Best-selling product in Taiwan</p>
5-injection regimen	Effect could be lasted for half a year with administrating 5 syringes continuously, 1 syringe per week.	5.5%	


Clinical Trials and Publications

1. The effect of three weekly intra-articular injections of hyaluronate on pain, function, and balance in patients with unilateral ankle arthritis. *J Bone Joint Surg Am.* 2011 Sep 21;93(18):1720-6.
2. Changes of synovial fluid protein concentrations in supra-patellar bursitis patients after the injection of different molecular weights of hyaluronic acid. *Exp Gerontol.* 2014 Apr;52:30-5.
3. Comparison of Single Intra-Articular Injection of Novel Hyaluronan (HYA-JOINT Plus) with Synvisc-One for Knee Osteoarthritis: A Randomized, Controlled, Double-Blind Trial of Efficacy and Safety. *J Bone Joint Surg Am.* 2017 Mar 15;99(6):462-471.
4. Origin and Efficacy of Hyaluronan Injections in Knee Osteoarthritis: Randomized, Double-Blind Trial. *Med Sci Monit.* 2018 Jul 9;24:4728-4737.
5. Improvement of self-reported functional scores and thickening of quadriceps and femoral intercondylar cartilage under ultrasonography after single intra-articular injection of a novel cross-linked hyaluronic acid in the treatment of knee osteoarthritis. *J Back Musculoskelet Rehabil.* 2018;31(4):709-718.
6. Safety and efficacy of single CHAP Hyaluronan injection versus three injections of linear Hyaluronan in pain relief for knee osteoarthritis: a prospective, 52-week follow-up, randomized, evaluator-blinded study. *BMC Musculoskelet Disord.* 2021 Jun 23;22(1):572.
7. Comparing efficacy of intraarticular single crosslinked Hyaluronan (HYAJOINT Plus) and platelet-rich plasma (PRP) versus PRP alone for treating knee osteoarthritis. *Sci Rep.* 2021 Jan 8;11(1):140.
8. Efficacy of Intra-Articular Injection of Biofermentation-Derived High-Molecular Hyaluronic Acid in Knee Osteoarthritis: An Ultrasonographic Study. *Cartilage.* 2022 Jan-Mar;13(1):19476035221077404.
9. Single Injection of Cross-Linked Hyaluronate in Knee Osteoarthritis: A 52-Week Double-Blind Randomized Controlled Trial. *Pharmaceutics.* 2022 Aug 25;14(9):1783.

The pain relief effect is better than Sanofi's one-injection product



The thickness of the quadriceps and cartilage improved significantly at 3 and 6 months after surgery.



The effect can be maintained for more than one year, with high satisfaction.


Table 3 Patient satisfaction in time interval

Time	CHAP-HA (N = 71)	Linear-HA (N = 69)	P value
4th week	66.4 ± 22.4	68.4 ± 24.7	0.622
12th week	73.2 ± 23.4	71.1 ± 25.2	0.601
26th week	73.4 ± 22.7	63.5 ± 26.5	< 0.018 [‡]
39th week	72.3 ± 22.4	52.1 ± 23.2	< 0.001 [‡]
52th week	61.7 ± 22.0	37.5 ± 23.1	< 0.001 [‡]

[‡] indicates a significant difference between groups (P < 0.05)

III. Absorbable Adhesion Barrier

Postsurgical adhesion



Gynecologic surgery



Tendon, peripheral nerve, joint surgery

III. Absorbable Adhesion Barrier

For gynecological pelvic surgery



Product advantages

- ✓ High Biocompatibility
- ✓ Easy to apply
- ✓ Shift resistance

For ligament, peripheral nerve, joint surgery



Product advantages


- ✓ High Biocompatibility
- ✓ Easy to apply
- ✓ Shift resistance
- ✓ Long effective protection time

Clinical Trials and Publications

1. A resorbable hyaluronic acid hydrogel to prevent adhesion in porcine model under laparotomy pelvic surgery. *J Appl Biomater Funct Mater*. Jan-Dec 2021;19.
2. Crosslinked Hyaluronic Acid Gels for the Prevention of Intrauterine Adhesions after a Hysteroscopic Myomectomy in Women with Submucosal Myomas: A Prospective, Randomized, Controlled Trial. *Life*. 2020 May 15;10(5):67.
3. Efficacy of Applying Hyaluronic Acid Gels in the Primary Prevention of Intrauterine Adhesion after Hysteroscopic Myomectomy: A Meta-Analysis of Randomized Controlled Trials. *Life*. 2020 Nov 15;10(11):285.

Product could effectively avoid or slow down the occurrence of postoperative adhesions.

Product could effectively avoid or slow down the occurrence of postoperative adhesions and was significantly better than competing products.




	CHA-P Gel (n = 24)	CHA Gel (n = 23)	No (n = 23)	<i>p</i> -Value
Intrauterine Adhesion				
No	22 (91.7%) ^a	19 (82.6%) ^a	14 (60.9%)	0.031
Yes	2 (8.3%) ^a	4 (17.4%) ^a	9 (39.1%)	
Modified AFS Stage				
0	22 (91.7%) ^b	19 (82.6%) ^b	14 (60.9%)	0.014
I (mild)	2 (8.3%) ^b	3 (13.0%) ^b	1 (4.3%)	
II (moderate)	0 ^b	1 (4.3%) ^b	4 (17.4%)	
III (severe)	0 ^b	0 ^b	4 (17.4%)	


The data are presented as number (percentage). CHA-P (PROTAHERE absorbable adhesion barrier[®], SciVision Biotech Inc., Kaohsiung, Taiwan); CHA gel (Hyalobarrier[®] gel, Baxter, Pisa, Italy). No: no anti-adhesive agent gel treatment. AFS: American Fertility Society. ^a and ^b: The comparison between the CHA-P gel and CHA gel (^a: *p*-value = 0.352, ^b: *p*-value = 0.497).

IV. Intravesical Instillation

HYAURO[®] Intravesical Instillation



HYAURO Intravesical Instillation



Product Specification

PACKAGE : 50 mL per vial

ACTIVE INGREDIENT: Sodium Hyaluronate 40mg

DESCRIPTION


The glycosaminoglycan (GAG) layer on the luminal surface of the bladder wall is the primary defense mechanism which can provide a protective barrier to against microorganisms, carcinogens, crystals and other agents present in the urine. HYAURO Intravesical Instillation has been developed to temporarily replenish the deficient GAG layer on the bladder epithelium.

INDICATION

The product is indicated for cystitis-associated GAG layer deficiency such as interstitial cystitis and cystitis caused by infection, trauma, urinary stones, urine retention, tumors and radiation.




Core Products of SciVision




Facial Aesthetics



Geriatrics care



Surgery



Urinary



Outline

1. Company & Product & Technology
Overview

2. Business Operation

Profit & Loss-Consolidated

Profit & Loss-Consolidated


Unit:NT thousand dollars
(except for EPS)

	2022/1/1~2022/9/30 (Reviewed)		2021/1/1~2021/9/30 (Reviewed)		Annual growth rate
Revenue	397,481	100%	365,302	100%	8.8%
Cost of Goods Sold	(139,396)	-35%	(119,614)	-33%	16.5%
Gross Profit	258,085	65%	245,688	67%	5.0%
Operating Expense	(166,604)	-42%	(155,613)	-42%	7.1%
Operating Income	91,481	23%	90,075	25%	1.6%
Non-operating Income, Net	45,583	11%	(5,754)	-2%	-892.2%
Income before Tax	137,064	34%	84,321	23%	62.6%
Net Income	112,169	28%	76,354	21%	46.9%
EPS(NT\$)	1.69		1.15		

Domestic and International Sales Ratio


2022 Jan.~Sep. & 2021 Jan.~Sep.

2022/1/1~2022/9/30



■ Domestic ■ International

2021/01/01~2021/9/30




■ Domestic ■ International

Product Portfolio Sales Ratio

2022 Jan.~Sep. & 2021 Jan.~Sep.

2022/1/1~2022/9/30


1.59%



■ Hyaluronic Acid Medical Device ■ Other

2021/01/01~2021/9/30

0.47%



■ Hyaluronic Acid Medical Device ■ Other

Balance Sheet-Consolidated

Balance Sheet-Consolidated

Unit:NT thousand dollars

	2022/9/30 (Reviewed)		2021/9/30 (Reviewed)	
Cash and Cash Equivalents	837,869	35%	685,416	30%
Accounts Receivable	63,018	3%	62,265	3%
Inventories	97,509	4%	67,591	3%
Current Financial Assets at Fair Value through Profit or Loss	58,843	2%	-	0%
Amortized Cost Financial Assets	-	0%	36,593	2%
Property, Plant & Equipment	1,171,064	50%	1,270,135	56%
Other Current/Non-Current Assets	140,207	6%	161,645	6%
Total Assets	2,368,510	100%	2,283,645	100%
Current Liabilities	121,013	5%	463,397	20%
Long-Term & Other Liabilities	779,241	33%	398,287	18%
Total Liabilities	900,254	38%	861,684	38%
Total Shareholders' Equities	1,468,256	62%	1,421,961	62%
Key Indices				
A/R Turnover (Days)	48.69		48.77	
Inventory Turnover (Days)	177.15		129.87	
Current Ratio(x)	895.15%		191.22%	
Net Profit Margin(%)	28.22%		20.90%	


Cash Flows-Consolidated

Cash Flows-Consolidated


<i>Unit:NT thousand dollars</i>	2022/1/1~2022/9/30 (Reviewed)	2021/1/1~2021/9/30 (Reviewed)
From Operating Activities	141,535	82,218
Profit before tax	137,064	84,321
Depreciation & Amortisation	46,050	36,015
Net change in working capital	(41,579)	(38,118)
From Investing Activities	36,833	(93,173)
amortised cost	44,316	(20,848)
through Profit or Loss	(58,137)	0
Capital expenditure	(5,822)	(20,988)
Net change in Investing item	56,476	(51,337)
From Financing Activities	584	299,007
Short-term loans	(304,523)	0
Long-term loans	0	300,000
Net change in Fincncing item	305,107	(993)
Net Change in Cash	178,952	288,052
Beginning Balance	658,917	397,364
Ending Balance	837,869	685,416
Free Cash Flow	135,713	61,230

HEALTHY CASHFLOW AND EXPANDING PROFIT


Revenue




Gross and Operating Margin



Net Profit



Cash Generated From Operations Before Interest And Taxes



Our Vision



Science Creates Better Visions